Antibodies for respiratory virus that can cause a rare polio-like disease that causes paralysis in children have been identified by a team of researchers at Purdue University, Vanderbilt University Medical Center and the University of Wisconsin. The virus, enterovirus 68, has binding sites for the antibodies. The structural analysis of the virus shows that the antibody binding sites (shown here in gold and blue) do not overlap. Courtesy of Purdue University image/Richard Kuhn
Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.
The illness, called acute flaccid myelitis (AFM), causes sudden weakness in the arms and legs following a fever or respiratory illness. More than 600 cases have been identified since the U.S. Centers for Disease Control and Prevention began tracking the disease in 2014.
There is no specific treatment for AFM, which tends to strike in the late summer or early fall and which has been associated with some deaths. However, the disease has recently been linked to a group of respiratory viruses called enterovirus D68 (EV-D68).
Researchers at the Vanderbilt Vaccine Center isolated antibody-producing blood cells from the blood of children who had previously been infected by EV-D68. By fusing the blood cells to fast-growing myeloma cells, the researchers were able to generate a panel of monoclonal antibodies that potently neutralized the virus in laboratory studies.
Colleagues at Purdue determined the structure of the antibodies, which shed light on how they specifically recognize and bind to EV-D68. One of the antibodies protected mice from respiratory and neurologic disease when given either before or after infection by the enterovirus.
"We were excited to isolate potent human antibodies that inhibit this devastating polio-like virus, and these studies will form the basis for taking them forward to clinical trials," says Dr. James Crowe, director, Vanderbilt Vaccine Center; Ann Scott Carell Chair and professor of pediatrics and pathology, microbiology and immunology in the Vanderbilt University School of Medicine.
Source: Purdue University
710327 860197This design is wicked! You definitely know how to keep a reader entertained. Between your wit and your videos, I was almost moved to start my own blog (well, almost…HaHa!) Great job. I really loved what you had to say, and more than that, how you presented it. Too cool! 762398